Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, Harmony L. Tyner, Sarang K. Yoon, Jennifer K. Meece, Lauren E.W. Olsho, Alberto J. Caban‐Martinez, Ashley Fowlkes, Karen Lutrick, Jennifer L. Kuntz, Kayan Dunnigan, Marilyn J. Odean, Kurt T. Hegmann, Elisha Stefanski, Laura Edwards, Natasha Schaefer Solle, Lauren Grant, Katherine Ellingson, Holly C. Groom, Tnelda Zunie, Matthew S. Thiese, Lynn Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael Smith, Andrew L. Phillips, Kimberly Groover, Young M. Yoo, Joe K. Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, Shawn C. Beitel, Tyler Morrill, Josephine Mak, Patrick Rivers, Katherine M. Harris, Danielle Rentz Hunt, Melissa Arvay, Preeta K. Kutty, Alicia M. Fry, Manjusha Gaglani
Abstract
In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.